IFNG and neoplasm: HLA-DR is involved in the suppression of tumour growth, whereby it presents tumour-associated antigens (TAA) that are recognised by CD4+ T cells, which then produce cytokines, such as interleukins and interferon-γ (IFN-γ), to inhibit tumour growth [20,21].